Pharma M&A Biomedical in the north

The Northern Factor and Scientific Research

Whilst the news has been dominated by Pfizer and AstraZeneca, there has been a very different story developing in the north of the UK. The Northern Health Science Alliance (NHSA) has brought together eight universities, eight NHS trusts and announced links with foreign companies, from the US and Sweden to develop new products and create ‘an internationally recognized life science …

Pharma M&A Pfizer Questioned by Government

Pfizer questioned in Parliament

Pfizer’s chief Executive Ian Read is being questioned today in Parliament over Pfizer’s potential takeover bid of AstraZeneca and its commitment to the UK.   Ian Read will be subject to hostile questions in parliament today over his proposed bid for AstraZeneca. However it wont merely be Pfizer that will be questioned, AstraZeneca’s CEO Pascal Soriot and business minister Vince …

Pharma M&A Briefing: AstraZeneca rejects Pfizer

AstraZeneca rejects Pfizer’s new proposal

Pfizer increased its offer to AstraZeneca to £50 a share today, putting pressure on the UK pharmaceuticals group to open discussions, in what could lead to a deal that would create the world’s largest drugs company. However within hours AstraZeneca has once again refused to come to the table. In a statement released today, AstraZeneca have stated that the terms outlined …

Pharma M&A AstraZeenec and Pfizer Chess Game

Pharma M&A Chess: Who moves next – AstraZeneca or Pfizer?

Pfizer’s intentions on AstraZeneca involve the playing of a high stakes strategic chess game, with each side plotting carefully their next move. Pfizer has until May 26th to make a firm bid on AstraZeneca or walk away and with the episode in the public eye, it will be interesting to see what moves each company makes in the next few …

Pharma M&A Stocks Soaring due to Glaxo and Novartis deal

Pharma M&A activity spurring stocks higher and higher

UK Stocks in Novartis, AstraZeneca and GlaxoSmithKline rose for a third day yesterday, amid Glaxo’s transaction with Novartis and rumors of a takeover of AstraZeneca by Pfizer. It seems that investors are focusing on the pharmaceuticals M&A industry to shore up global stock markets.   As reported in The Guardian the drugs industry was gripped by ‘merger and acquisition fever’ …

Pharma M&A Forecast Sunny

Sunny with little chance of rain: Pharma M&A forecast

Pharma M&A activity is hot out the blocks for the first quarter, with activity in the Pharma, Medical & Biotech sector totaling $63.4 billion, higher than its 2013 counterpart at $14.2 billion.   On 9th April Mergermarket released its Global Q1 2014  Pharma, Medical & Biotech M&A Trend Report,  identifying large scale growth in the pharmaceutical sector, compared to last year. …

big pharma firepower in global pharma m&a

Big pharma’s position in global pharma M&A – exploring EY’s ‘Firepower’ report

Last year saw pharmaceutical mergers and acquisitions increase by $45 billion (click here to read a recent Total Biopharma post about it). However, the activities of big pharma in these M&As were somewhat marginalised, with the majority of acquisitions completed by speciality pharma and big biotech. As reported in Financier.com, Ernst & Young’s report, ‘Firepower and Growth Gap’, states that …

pharma m&a

Strong pharma M&A activity expected in 2014

After poor performance in 2012, it appears that pharma M&A has rebounded! According to a recent PwC report, the pharma industry saw deal value increase by $45 billion in 2013—a 45.8% increase from 2012. According to PwC’s U.S. Pharmaceutical and Life Sciences Deals Leader, Dimitri Drone, they “expect the momentum of M&A activity in the fourth quarter […] to continue into 2014 …

What a “surprise”, Neostem is hot!

On a recent release by Aegis Capital the NY-based biotech Neostem has been upgraded to a buy rating and a $2.5 price target. The company which has been undervalued in the cell therapy industry, has four promising platforms, including its leading candidate AMR-001 for repair of heart muscle function following an acute myocardial infarction. Most of the company's upgraded rating …

Takeda set to acquire Brazilian-based Multilab

Takeda Pharmaceuticals and leading Brazilian pharmaceutical company Multilab have signed an agreement for Takeda to acquire Multilab. Takeda hopes to finalise the acquisition by the second quarter of the fiscal year 2012. Takeda Brazil will spend 500 million (BRL) upfront to purchase Multilab and a further 40 million (BRL) in milestone payments to the owners of Multilab. This acquisition will …